The impact of the changing pneumococcal national immunisation program among older Australians

Australia has a universal infant pneumococcal conjugate vaccination program and until recently polysaccharide vaccine for non-Indigenous adults aged ?65 years Indigenous ?50 years. We documented the impacts of adult programs on epidemiology invasive disease (IPD) in adults. IPD notifications from National Notifiable Disease Surveillance System were analysed 2002 to 2017, grouped by age, serotype group status. Since funding elderly January 2005, total decreased 19% but doubled Vaccine uptake was suboptimal both groups lower due serotypes contained vaccines (PCV) except 3 declined markedly over study period replaced non-PCV serotypes. Serotype is currently most common older In populations eligible 23-valent (23vPPV) program, rates its exclusive increased extent than non-vaccine types. accounted population 23vPPV while it's eleven majority younger Infant have shaped serotype-specific remains significant health burden population. Herd immunity impact clear PCV excluding replacement evident The immunisation appears partially curbed with serotypes, highlighting potential benefit increasing coverage Australia.